IRIS
LOPETUSO, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.422
AS - Asia 1.766
EU - Europa 1.627
SA - Sud America 471
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 7
Totale 7.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.340
SG - Singapore 1.030
IE - Irlanda 477
BR - Brasile 378
IT - Italia 376
SE - Svezia 274
CN - Cina 252
VN - Vietnam 204
RU - Federazione Russa 118
DE - Germania 94
HK - Hong Kong 72
GB - Regno Unito 55
CA - Canada 47
AR - Argentina 46
AT - Austria 34
IN - India 34
FR - Francia 26
MX - Messico 23
JP - Giappone 22
NL - Olanda 21
FI - Finlandia 20
ID - Indonesia 19
PL - Polonia 19
BD - Bangladesh 18
EC - Ecuador 18
TW - Taiwan 17
BE - Belgio 16
RO - Romania 16
ES - Italia 15
ZA - Sudafrica 15
IR - Iran 14
UA - Ucraina 14
IQ - Iraq 13
CO - Colombia 12
TH - Thailandia 12
TR - Turchia 12
EG - Egitto 10
BG - Bulgaria 9
KR - Corea 9
PE - Perù 7
PK - Pakistan 7
AU - Australia 6
LU - Lussemburgo 6
EU - Europa 5
HR - Croazia 5
NP - Nepal 5
SA - Arabia Saudita 5
TN - Tunisia 5
CH - Svizzera 4
LT - Lituania 4
MY - Malesia 4
UZ - Uzbekistan 4
VE - Venezuela 4
DK - Danimarca 3
HU - Ungheria 3
PY - Paraguay 3
RS - Serbia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BY - Bielorussia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
KE - Kenya 2
KG - Kirghizistan 2
MA - Marocco 2
ME - Montenegro 2
NG - Nigeria 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
SC - Seychelles 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
CL - Cile 1
DZ - Algeria 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
KZ - Kazakistan 1
MT - Malta 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 7.342
Salva come PNG Salva come JPEG
Città #
Chandler 766
Singapore 688
Dublin 477
Dallas 253
Princeton 234
Ashburn 216
Jacksonville 191
Altamura 114
Dong Ket 93
Los Angeles 88
Santa Clara 86
Wilmington 85
Beijing 71
Redondo Beach 66
Hong Kong 62
Ann Arbor 57
Ho Chi Minh City 56
Buffalo 49
Chieti 43
The Dalles 42
Rome 39
New York 34
Nuremberg 34
São Paulo 31
Pescara 30
Falls Church 27
Munich 23
Hanoi 21
London 19
Taranto 19
Norwalk 17
Brussels 16
Frankfurt am Main 16
Teramo 16
Chicago 15
Tokyo 15
Rio de Janeiro 14
Stockholm 14
Hefei 13
Montreal 12
Pune 12
Atlanta 11
Moscow 11
Xitun 11
Cluj-Napoca 10
Columbus 10
Guangzhou 10
Tongling 10
Vienna 10
Brasília 9
Edinburgh 9
Helsinki 9
San Jose 9
Toronto 9
Warsaw 9
Belo Horizonte 8
Sofia 8
Washington 8
Boardman 7
Curitiba 7
Houston 7
Lappeenranta 7
Macerata 7
Porto Alegre 7
San Francisco 7
Ankara 6
Calgary 6
Denver 6
Guglionesi 6
Johannesburg 6
Milan 6
Phoenix 6
Seoul 6
Tehran 6
Baghdad 5
Bangkok 5
Bologna 5
Brooklyn 5
Chiang Mai 5
Council Bluffs 5
Guayaquil 5
Lima 5
Manchester 5
Quito 5
Seattle 5
Stoke-on-Trent 5
Tarumichō 5
Woodbridge 5
Amsterdam 4
Bari 4
Cairo 4
Dhaka 4
Hangzhou 4
Jakarta 4
Kuala Lumpur 4
Luxembourg 4
Mexico City 4
Naples 4
Salvador 4
Santa Maria 4
Totale 4.556
Salva come PNG Salva come JPEG
Nome #
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): Preliminary results from a retrospective cohort study 151
Assessment of crohn’s disease activity: Magnetic resonance enterography in comparison with clinical and endoscopic evaluations 131
13C-octanoic acid breath test to study gastric emptying time 118
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 107
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 102
Akkermansia muciniphila: Key player in metabolic and gastrointestinal disorders 94
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 88
Bacillus clausii and gut homeostasis: state of the art and future perspectives 87
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 85
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 83
Role of yeasts in healthy and impaired gut microbiota: The gut mycome 83
Characterization of sarcopenia in an IBD population attending an Italian gastroenterology tertiary center 80
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 79
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 78
Role of Helicobacter pylori infection on nutrition and metabolism 78
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 78
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 76
Proteobacteria: A common factor in human diseases 74
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila 74
The gastrointestinal microbiome - Functional interference between stomach and intestine 73
Commensal Clostridia: Leading players in the maintenance of gut homeostasis 73
Food components and dietary habits: Keys for a healthy gut microbiota composition 73
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis 71
Beyond the HLA Genes in Gluten-Related Disorders 71
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 70
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 70
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 70
Ulcerative colitis 69
Opposing functions of classic and novel IL-1 family members in gut health and disease 69
Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system 69
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 69
A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis 68
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 68
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for ‘gut barrier protectors’ in IBD? 68
The gut barrier: New acquisitions and therapeutic approaches 67
Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice 67
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 66
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 65
Bacteriocins and bacteriophages: Therapeutic weapons for gastrointestinal diseases? 65
Coordinated Multi-Language Translation of A Validated Symptom Questionnaire for Carbohydrate Intolerances: A Practical Structured Procedure 64
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 64
Gut microbiota and inflammatory bowel disease: So far so gut! 64
IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair 64
Dietary magnesium alleviates experimental murine colitis through upregulation of the transient receptor potential melastatin 6 channel 64
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease 64
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection 63
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 63
Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment 63
Gut Virome and Inflammatory Bowel Disease 62
Microbiota and inflammatory bowel disease: An update 62
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders 62
European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease 62
Can we predict the efficacy of anti-TNF-α agents? 61
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 60
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 60
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin 59
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries 59
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 59
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: Where we stand and future perspectives 59
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 59
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 59
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications 59
Commentary to “safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease” 58
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 58
The use of anti-spasmodics in the treatment of irritable bowel syndrome: Focus on otilonium bromide 58
Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea 58
Assessment of neurological manifestations in hospitalized patients with COVID-19 58
Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities 57
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 57
Bariatric procedures and microbiota: patient selection and outcome prediction 57
Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor-Independent Ulcerative Colitis 57
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors 56
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 56
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 56
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 55
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center 55
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis 55
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 54
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 54
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 53
Relationship between oral microbiota and periodontal disease: A systematic review 52
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 52
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 52
Diagnosis of Cholangiocarcinoma: The New Biological and Technological Horizons 51
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 51
Prevalence of severe irritable bowel syndrome among Italian adults. A meta-analysis 51
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study 51
The use of probiotics in different phases of diverticular disease 50
Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility 50
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease 49
European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus 49
Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis 48
Gut microbiota during dietary restrictions: New insights in non-communicable diseases 48
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 47
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 47
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases 47
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 46
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 46
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 46
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 46
Totale 6.533
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.646
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.646
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021285 0 0 0 0 0 135 12 10 10 6 16 96
2021/2022705 53 3 3 118 20 16 11 28 54 39 60 300
2022/20231.882 241 337 89 224 95 348 120 143 169 18 81 17
2023/2024849 53 36 47 51 36 186 235 87 14 37 13 54
2024/20251.774 158 348 191 54 36 112 82 96 305 84 163 145
2025/20261.862 257 152 583 463 382 25 0 0 0 0 0 0
Totale 7.854